presentation by Philip Smith, CEO, 4D Biomaterials
4D Biomaterials is introducing a new class of 3D printing resin-inks for medical applications. In this first public presentation of the company’s technology, we will outline the unique properties of the materials including their biocompatibility, degradation/resorption behaviour and physical characteristics.
What drives you?
Passion for innovation, building new enterprises and raising three daughters.
Why should the delegate attend your presentation?
This platform technology has the potential to disrupt the medical 3D printing sector so delegates will want to discover what opportunities it might present for them.
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
In the long run, I think new biomaterials will offer the greatest potential because they will overcome the limitations of incumbent technologies and open up new worlds of innovation.
What kind of impact do you expect them to have?
Improved patient experiences and outcomes, and efficiencies for healthcare providers.
What are the barriers that might stand in the way?
Proving the in-human safety and efficacy of new implantable devices made from such new materials, overcoming caution and conservatism in the adoption of new technology and defensive reactions from incumbent suppliers of established products.
Start with the end in mind and keep going until you get there!
Philip Smith is a university spin-out veteran with a background in mechanical engineering and materials technology. Career achievements include successfully introducing the world’s first commercially viable fluidic water meter, playing a key role in the formation of three chemistry-based spin outs from the Universities of Warwick and Birmingham and having a very minor part in the development of the fuel control system for the Rolls Royce Pegasus aero-engine. Phil became a Chartered Engineer in the 90’s and holds an MBA from Warwick Business School.
4D Biomaterials is the trading name of 4D Medicine Ltd, a company that was spun out from the Universities of Birmingham and Warwick in April 2020.
Our mission is to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffold implants to help patients recover from major medical procedures. The polycarbonate-based resins, developed by our founders Professor Andrew Dove and Dr Andrew Weems, are novel bioresorbable materials with good shape memory, tunable mechanical and chemical properties and promising tissue-healing performance. The composition of the resins is protected by a family of patents exclusively licensed to the company as part of the spin-out process.
Philip Smith will be speaking at the 2021 edition of the conference.